Differential expression of GSPT1 GGCn alleles in cancer

Cancer Genetics and Cytogenetics

Volumn 195, Issue 2, 2009, Pages 132-142

  Malta Vacas, Joana ^a   Ferreira, Paula ^a   Monteiro, Carolino ^b   Brito, Miguel ^a  

^a INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; G1 TO S PHASE TRANSITION 1 PROTEIN; GENOMIC DNA; GLYCINE; MESSENGER RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; CROHN DISEASE; CYTOKINESIS; DNA METHYLATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOID CELL LINE; MICRONUCLEUS; MITOSIS SPINDLE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SHORT TANDEM REPEAT; UPREGULATION;

ALLELES; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MICRONUCLEUS TESTS; PEPTIDE TERMINATION FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TANDEM REPEAT SEQUENCES;

ALIAS; EUKARYOTA;

EID: 70949095595     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.08.010     Document Type: Article

References (42)

1. Zhouravleva G., Frolova L., Le Goff X., Le Guellec R., Inge-Vechtomov S., Kisselev L., and Philippe M. Termination of translation in eukaryotes in governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 14 (1995) 4065-4072
2. Ozawa K., Murakami Y., Eki T., Yokoyama K., Soeda E., Hoshino S., Ui M., and Hanaoka F. Mapping of the human GSPT1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p13.1. Somat Cell Mol Genet 18 (1992) 189-194
3. Hansen L.L., Jakobsen C.G., and Justesen J. Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23→p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet 86 (1999) 250-251
4. Hoshino S., Imai M., Mizutani M., Kikuchi Y., Hanaoka F., Ui M., and Katada T. Molecular cloning of a novel member of the eukaryotic polypeptide releasing factors (eRF): its identification as eRF3 interacting with eRF1. J Biol Chem 273 (1998) 22254-22259
5. Brito M., Malta-Vacas J., Carmona B., Aires C., Costa P., Martins A.P., Ramos S., Conde A.R., and Monteiro C. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility. Carcinogenesis 26 (2005) 2046-2049
6. Malta-Vacas J., Chauvin C., Gonçalves L., Nazaré A., Carvalho C., Monteiro C., Bagrel D., Jean-Jean O., and Brito M. eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development. Oncol Rep 21 (2009) 1551-1558
7. Tallheden T., Karlsson C., Brunner A., Van Der Lee J., Hagg R., Tommasini R., and Lindahl A. Gene expression during redifferentiation of human articular chondrocytes. Osteoarthritis Cartilage 12 (2004) 525-535
8. Chauvin C., Salhi S., Le Goff C., Viranaicken W., Diop D., and Jean-Jean O. Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation. Mol Cell Biol 25 (2005) 5801-5811
9. Hoshino S., Imai M., Kobayashi T., Uchida N., and Katada T. The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3′-Poly(A) tail of mRNA: direct association of erf3/GSPT with polyadenylate-binding protein. J Biol Chem 274 (1999) 16677-16680
10. Hosoda N., Kobayashi T., Uchida N., Funakoshi Y., Kikuchi Y., Hoshino S., and Katada T. Translation termination factor eRF3 mediates mRNA decay through the regulation of deadenylation. J Biol Chem 278 (2003) 38287-38291
11. Hoshino S., Hosoda N., Araki Y., Kobayashi T., Uchida N., Funakoshi Y., and Katada T. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/GSPT) in the mRNA degradation pathway. Biochemistry (Mosc) 64 (1999) 1367-1372
12. Uchida N., Hoshino S., Imataka H., Sonenberg N., and Katada T. A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in cap/poly(A)-dependent translation. J Biol Chem 277 (2002) 50286-50292
13. Hegde R., Srinivasula S.M., Datta P., Madesh M., Wassell R., Zhang Z., Cheong N., Nejmeh J., Fernandes-Alnemri T., Hoshino S., and Alnemri E.S. The polypeptide chain releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem 278 (2003) 38699-38706
14. Kodama H., Ito K., and Nakamura Y. The role of N-terminal domain of translational release factor eRF3 for the control of functionality and stability in S. cerevisiae. Genes Cells 12 (2007) 639-650
15. Volkov K., Osipov K., Valouev I., Inge-Vechtomov S., and Mironova L. N-terminal extension of Saccharomyces cerevisiae translation termination factor eRF3 influences the suppression efficiency of sup35 mutations. FEMS Yeast Res 7 (2007) 357-365
16. Chauvin C., Salhi S., and Jean-Jean O. Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway. Mol Cell Biol 27 (2007) 5619-5629
17. Basu J., Williams B.C., Li Z., Williams E.V., and Goldberg M.L. Depletion of a Drosophila homolog of yeast Sup35 p disrupts spindle assembly, chromosome segregation, and cytokinesis during male meiosis. Cell Motil Cytoskeleton 139 (1998) 286-302
18. Borchsenius A.S., Tchourikova A.A., and Inge-Vechtomov S.G. Recessive mutations in SUP35 and SUP45 genes coding for translation release factors affect chromosome stability in Saccharomyces cerevisiae. Curr Genet 37 (2000) 285-291
19. Valouev I.A., Kushnirov V.V., and Ter-Avanesyan M.D. Yeast polypeptide chain release factors eRF1 and eRF3 are involved in cytoskeleton organization and cell cycle regulation. Cell Motil Cytoskeleton 52 (2002) 161-173
20. Malta-Vacas J., Aires C., Costa P., Conde A.R., Ramos S., Martins A.P., Monteiro C., and Brito M. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types. J Clin Pathol 58 (2005) 621-625
21. Mecklin J.P. The implications of genetics in colorectal cancer. Ann Oncol 19 Suppl. 5 (2008) v87-v90
22. Zisman T.L., and Rubin D.T. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 14 (2008) 2662-2669
23. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 1-5
24. Sambrook J., and Russell D.W. Molecular cloning: a laboratory manual. 3rd ed. (2002), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
25. -ΔΔC T method. Methods 25 (2001) 402-408
26. Vermes I., Haanen C., Steffens-Nakken H., and Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184 (1995) 39-51
27. Deitch A.D., Law H., and deVere White R. A stable propidium iodide staining procedure for flow cytometry. J Histochem Cytochem 30 (1982) 967-972
28. Fenech M., Chang W.P., Kirsch-Volders M., Holland N., Bonassi S., and Zeiger E. HUman MicroNucleus Project. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 534 (2003) 65-75
29. Raymond M., and Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 86 (1995) 248-249
30. Sokal R.R., and Rohlf J.F. Biometry: the principles and practice of statistics in biological research. 3rd ed. (1995), W.H. Freeman, New York
31. Allavena P., Garlanda C., Borrello M.G., Sica A., and Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18 (2008) 3-10
32. Malta-Vacas J., Nolasco S., Monteiro C., Soares H., and Brito M. Translation termination and protein folding pathways are up-regulated in gastric cancer. Clin Chem Lab Med 47 (2009) 427-431
33. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet (2007) R50-R59 16 Spec No 1
34. Dunn B.K. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 983 (2003) 28-42
35. Pal S.K., and Pegram M. HER2 targeted therapy in breast cancer... beyond Herceptin. Rev Endocr Metab Disord 8 (2007) 269-277
36. Park J.W., Neve R.M., Szollosi J., and Benz C.C. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8 (2008) 392-401
37. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
38. Verhagen A.M., Kratina T.K., Hawkins C.J., Silke J., Ekert P.G., and Vaux D.L. Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. Cell Death Differ 14 (2007) 348-357
39. Eastmond D.A., and Tucker J.D. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes, and an antikinetochore antibody. Environ Mol Mutagen 13 (1989) 34-43
40. Gisselsson D. Mitotic instability in cancer: is there method in the madness?. Cell Cycle 8 (2005) 1007-1010
41. Bonassi S., Znaor A., Ceppi M., Lando C., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Cebulska-Wasilewska A., Fabianova E., Fucic A., Hagmar L., Joksic G., Martelli A., Migliore L., Mirkova E., Scarfi M.R., Zijno A., Norppa H., and Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28 (2007) 625-631
42. Iarmarcovai G., Ceppi M., Botta A., Orsière T., and Bonassi S. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis. Mutat Res 659 (2008) 274-283